Tanvex BioPharma (TPE:6541) Total Equity: NT$5,694.0 Mil (As of Dec. 2025)


TPE:6541 Tanvex BioPharma Inc TPE:6541
57 GF Score
Price NT$41.40
GF Value NT$254.61
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Tanvex BioPharma Total Equity?

Tanvex BioPharma TPE:6541 +2.10% 57 Total Equity is NT$5,694.0 Mil as of Dec. 2025. GuruFocus rates TPE:6541 with a GF Score™ of 57/100 and a GF Value™ of NT$254.61 (Possible Value Trap). The stock has 4 warning signs investors should review.

Tanvex BioPharma's total equity for the quarter that ended in Dec. 2025 was NT$5,694.0 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Tanvex BioPharma Total Equity Historical Data

* Premium members only.

The historical data trend for Tanvex BioPharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tanvex BioPharma Total Equity Chart

Tanvex BioPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,794.80 1,391.48 821.11 893.31 5,693.98

Tanvex BioPharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 893.31 5,549.23 4,874.16 6,001.65 5,693.98
TPE:6541
57GF Score
Tanvex BioPharma Inc TPE:6541
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tanvex BioPharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Tanvex BioPharma's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=7961.134-2267.152
=5,694.0

Tanvex BioPharma's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=7961.134-2267.152
=5,694.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$5,694.0 Mil mean?
Tanvex BioPharma (TPE:6541) has a Total Equity of NT$5,694.0 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Tanvex BioPharma and its competitors.
Is Tanvex BioPharma's Total Equity too high?
Tanvex BioPharma's current Total Equity is NT$5,694.0 Mil. Overall, Tanvex BioPharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's Total Equity compare to VRTX and REGN?
Tanvex BioPharma's Total Equity of NT$5,694.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Tanvex BioPharma and its competitors. Tanvex BioPharma's current Total Equity is NT$5,694.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Tanvex BioPharma (TPE:6541) is currently considered Possible Value Trap. The stock's GF Value™ is NT$254.61, compared to a current price of NT$41.40 — trading 83.7% below its estimated fair value. The current Total Equity is NT$5,694.0 Mil. Tanvex BioPharma's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current Total Equity is NT$5,694.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tanvex BioPharma (TPE:6541) Overvalued in 2026?

Based on GuruFocus' analysis, Tanvex BioPharma stock appears to be undervalued. The current stock price of NT$41.40 is trading 83.7% below its estimated GF Value™ of NT$254.61. GuruFocus considers Tanvex BioPharma to be Possible Value Trap.

Key valuation signals for TPE:6541:

  • Total Equity: NT$5,694.0 Mil
  • GF Value™: NT$254.61 vs. price of NT$41.40 (83.7% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the TPE:6541 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tanvex BioPharma Business Description

Address No. 12-2, Shengyi Road, Section 2, 6th Floor, Hsinchu County, Zhubei, TWN, 106
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
57GF Score

Get the complete analysis for TPE:6541

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$41.40
Price
NT$254.61
GF Value